Bristol-Myers Squibb Company vs Pfizer Inc.

Full side-by-side comparison — 2026

Data as of May 20, 2026 · Updated automatically

11
BMY Wins
0
Tie
8
PFE Wins

BMY

Price USD 59.24
P/E Ratio 16.0x
Div Yield 0.0440%
Beta 0.26
Sector Health Care

PFE

Price USD 25.89
P/E Ratio 19.3x
Div Yield 0.0680%
Beta 0.31
Sector Health Care

Price Overview

Metric BMY PFE
Current Price 59.24 25.89
Previous Close 58.54 25.79

Valuation

Metric BMY PFE
Trailing P/E 15.97 19.34
Forward P/E 9.24 8.93
Price / Book 5.80 1.67
Price / Sales 2.40 2.28
EV / EBITDA 8.03 7.71

Dividends & Income

Metric BMY PFE
Dividend Yield 0.0440% 0.0680%
Dividend Rate (Annual) 2.50 1.72
5-Year Avg Yield 3.55% 4.48%
Payout Ratio 0.6969% 1.3054%

Risk & Financial Health

Metric BMY PFE
Beta (Volatility) 0.26 0.31
Debt / Equity 230.97 71.60
Quick Ratio 1.18 0.85
Current Ratio 1.42 1.25

Growth & Profitability

Metric BMY PFE
Revenue Growth 0.0260% 0.0540%
Earnings Growth 0.0920% -0.1010%
Return on Equity 0.3873% 0.0831%
Revenue / Share 23.82 11.13
Trailing EPS 3.57 1.31
Forward EPS 6.17 2.84

Analyst Targets

Metric BMY PFE
Analyst Mean Target 63.32 29.19
Analyst High Target 75.00 36.00
Analyst Low Target 40.00 24.00

Bottom Line: BMY vs PFE

Bristol-Myers Squibb Company (BMY) leads on 11 of 19 comparable metrics.

Bristol-Myers Squibb Company is the stronger pick for growth investors, while Pfizer Inc. may appeal to value investors.

Bristol-Myers Squibb Company has a higher Earnings Growth (9.20% vs -10.10%), which indicates profits are growing more quickly
Bristol-Myers Squibb Company has a higher Return on Equity (38.73% vs 8.31%), which suggests more efficient use of shareholder capital
Pfizer Inc. has a lower Price / Book (1.67 vs 5.80), which may indicate the stock trades closer to its book value

This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.

BMY Bristol-Myers Squibb Company

Best for Growth Investors
• Higher Earnings Growth: 9.20%
• Higher Return on Equity: 38.73%
• Higher Forward EPS: 6.17
Best for Conservative Investors
• Lower Beta (Volatility): 0.26
• Higher Quick Ratio: 1.18
• Higher Current Ratio: 1.42

PFE Pfizer Inc.

Best for Value Investors
• Lower Forward P/E: 8.93
• Lower Price / Book: 1.67
• Lower Price / Sales: 2.28
Best for Income Investors
• Higher Dividend Yield: 6.80%
• Higher 5-Year Avg Yield: 4.48%

Watch Out

BMY carries 231x debt-to-equity — significantly higher than PFE's 72x. High leverage amplifies both gains and losses.

Analyst Upside / Downside

BMY
+6.9%
PFE
+12.7%

Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.

About These Companies

Bristol-Myers Squibb Company (BMY)

Health Care · United States · NYQ

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; …

View BMY details →

Pfizer Inc. (PFE)

Health Care · United States · NYQ

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, …

View PFE details →

Frequently Asked Questions

Which has a better dividend yield, BMY or PFE?
Pfizer Inc. currently has the higher dividend yield. Bristol-Myers Squibb Company (BMY) yields 4.40% while Pfizer Inc. (PFE) yields 6.80%. Past dividends do not guarantee future payments.
Which is more volatile, BMY or PFE?
Pfizer Inc. is more volatile based on beta. Bristol-Myers Squibb Company has a beta of 0.26 and Pfizer Inc. has a beta of 0.30. A beta above 1.0 means higher volatility than the overall market.
Which is cheaper by P/E ratio, BMY or PFE?
Bristol-Myers Squibb Company has the lower trailing P/E ratio. Bristol-Myers Squibb Company trades at 16.0x earnings while Pfizer Inc. trades at 19.3x. A lower P/E may suggest better relative value, but could also reflect lower growth expectations.
Which has more analyst upside, BMY or PFE?
Based on mean analyst price targets, Pfizer Inc. has more upside potential. Bristol-Myers Squibb Company has +6.9% upside and Pfizer Inc. has +12.7% upside from current prices. Analyst estimates are not guaranteed.
Can I track both BMY and PFE in one portfolio?
Yes. AllInvestView lets you add both Bristol-Myers Squibb Company and Pfizer Inc. to the same portfolio and monitor price changes, dividends, total return, and allocation — completely free.

Track BMY and PFE in Your Portfolio

Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.

Start Free Portfolio

Related Comparisons

Health Care Peers

Stock Pages